{"content":"<li class=\"n-box-item date-title\" data-end=\"1513400399\" data-start=\"1513314000\" data-txt=\"Monday, December 23, 2019\">Friday, December 15, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3318772\" data-ts=\"1513384086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALSK\" target=\"_blank\">ALSK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318772-alaska-comms-closes-up-after-investor-notes-strategic-push\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alaska Comms closes up after investor notes strategic push</a></h4><ul>   <li>Alaska Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/ALSK' title='Alaska Communications Systems Group, Inc.'>ALSK</a>) finished the day <font color='green'>up 3.2%</font> after today's <a href=\"https://www.sec.gov/Archives/edgar/data/1089511/000114420417063823/tv481426_sc13d.htm\" target=\"_blank\">disclosure by TAR Holdings</a> and its sole member, Karen Singer, that the firm has a 5% stake and had approached management to urge a sale of the business or some assets.</li>    <li>\"TAR Holdings is also considering whether to seek representation on the Issuer&rsquo;s Board of Directors,\" the firm's 13D filing continues.</li>    <li>The company's <a href=\"https://seekingalpha.com/pr/17028694-alaska-communications-comments-schedule-13d-filing-karen-singer-group\" target=\"_blank\">issued an evening response</a> to the filing, saying it values shareholder opinions and constructive input.</li>    <li>\"Alaska Communications has engaged in various discussions with representatives of Ms. Singer and expects to continue a constructive dialogue,\" the company says, adding it regularly reviews strategic priorities and opportunities and that it's committed to enhancing value for all shareholders.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318772\" data-linked=\"Alaska Comms closes up after investor notes strategic push\" data-tweet=\"$ALSK - Alaska Comms closes up after investor notes strategic push https://seekingalpha.com/news/3318772-alaska-comms-closes-up-after-investor-notes-strategic-push?source=tweet\" data-url=\"https://seekingalpha.com/news/3318772-alaska-comms-closes-up-after-investor-notes-strategic-push\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318760\" data-ts=\"1513377319\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318760-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/ERII' title='Energy Recovery, Inc.'>ERII</a> <font color='green'>+4.7%</font>. <a href='https://seekingalpha.com/symbol/ERII' title='Energy Recovery, Inc.'>ERII</a> <font color='green'>+3.7%</font>. <a href='https://seekingalpha.com/symbol/AQ' title='Aquantia Corp.'>AQ</a> <font color='green'>+3.4%</font>. <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='green'>+2.7%</font>. <a href='https://seekingalpha.com/symbol/DRD' title='DRDGOLD Limited'>DRD</a> <font color='green'>+2.6%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/PETX' title='Aratana Therapeutics'>PETX</a> <font color='red'>-8.4%</font>. <a href='https://seekingalpha.com/symbol/JRJC' title='China Finance Online Co. Limited'>JRJC</a> <font color='red'>-7.3%</font>. <a href='https://seekingalpha.com/symbol/FRTA' title='Forterra'>FRTA</a> <font color='red'>-4.3%</font>. RSO <font color='red'>-4.3%</font>. <a href='https://seekingalpha.com/symbol/MACK' title='Merrimack Pharmaceuticals'>MACK</a> <font color='red'>-3.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318760\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$ERII $AQ $MRNS - After Hours Gainers / Losers https://seekingalpha.com/news/3318760-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3318760-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318744\" data-ts=\"1513375070\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBKR\" target=\"_blank\">IBKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318744-td-ameritrade-allowing-bitcoin-futures-trading-shares-up-2_6-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TD Ameritrade allowing Bitcoin futures trading; shares up 2.6% after hours</a></h4><ul><li>Bitcoin futures trading got off to a slow start after opening for acton at the CBOE on Sunday evening. Coming this Sunday is the start of futures trading at the CME - a far busier futures platform than the CBOE.</li><li>But what of the retail brokerages? Thus far, only Interactive Brokers (IEX:<a href='https://seekingalpha.com/symbol/IBKR' title='Interactive Brokers Group, Inc.'>IBKR</a>) is offering access to futures trading, and with a very high margin (50%). They're about to be joined by TD Ameritrade (NASDAQ:<a href='https://seekingalpha.com/symbol/AMTD' title='TD Ameritrade Holding Corporation'>AMTD</a>), which just announced <a href=\"https://www.cnbc.com/amp/2017/12/15/bitcoin-futures-are-about-to-get-another-big-boost.html?__twitter_impression=true\" target=\"_blank\">its intention to allow</a>&nbsp;clients to trade Bitcoin futures, starting Monday.</li><li>AMTD was&nbsp;<font color='green'>higher by 2.15%&nbsp;</font>in the regular session, and&nbsp;<font color='green'>up another 2.6%&nbsp;</font>after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318744\" data-linked=\"TD Ameritrade allowing Bitcoin futures trading; shares up 2.6% after hours\" data-tweet=\"$IBKR $IBKR $AMTD - TD Ameritrade allowing Bitcoin futures trading; shares up 2.6% after hours https://seekingalpha.com/news/3318744-td-ameritrade-allowing-bitcoin-futures-trading-shares-up-2_6-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3318744-td-ameritrade-allowing-bitcoin-futures-trading-shares-up-2_6-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318734\" data-ts=\"1513374268\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318734-weekly-etf-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weekly ETF Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/KOL' title='VanEck Vectors Coal ETF'>KOL</a> <font color='green'>+3.8%</font>. <a href='https://seekingalpha.com/symbol/GDXJ' title='VanEck Vectors Junior Gold Miners ETF'>GDXJ</a> <font color='green'>+3.7%</font>. <a href='https://seekingalpha.com/symbol/REMX' title='VanEck Vectors Rare Earth/Strategic Metals ETF'>REMX</a> <font color='green'>+3.2%</font>. <a href='https://seekingalpha.com/symbol/AMJ' title='JPMorgan Alerian MLP Index ETN'>AMJ</a> <font color='green'>+3.1%</font>. <a href='https://seekingalpha.com/symbol/URA' title='Global X Uranium ETF'>URA</a> <font color='green'>+2.3%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a> <font color='red'>-11.5%</font>. <a href='https://seekingalpha.com/symbol/VXX' title='iPath S&P 500 VIX Short-Term Futures ETN'>VXX</a> <font color='red'>-7.1%</font>. <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a> <font color='red'>-5.6%</font>. <a href='https://seekingalpha.com/symbol/SDY' title='SPDR Dividend ETF'>SDY</a> <font color='red'>-2.9%</font>. <a href='https://seekingalpha.com/symbol/FCG' title='First Trust Natural Gas ETF'>FCG</a> <font color='red'>-2.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318734\" data-linked=\"Weekly ETF Gainers / Losers\" data-tweet=\"$KOL $GDXJ $REMX - Weekly ETF Gainers / Losers https://seekingalpha.com/news/3318734-weekly-etf-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3318734-weekly-etf-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318728\" data-ts=\"1513373128\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PETX\" target=\"_blank\">PETX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318728-aratanas-stem-cell-candidateminus-016-flunks-osteoarthritis-study-in-dogs-development\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aratana&#39;s stem cell candidate AT-016 flunks osteoarthritis study in dogs, further development uncertain; shares down 10% after hours</a></h4><ul><li>Pet med developer Aratana Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PETX' title='Aratana Therapeutics'>PETX</a>) <a href=\"https://seekingalpha.com/pr/17028607-aratana-therapeutics-announces-study-resultsminus-016\" target=\"_blank\">announces </a>that a study evaluating allogeneic stem cell therapy AT-016 for the treatment of osteoarthritis in dogs failed to meet the criteria for efficacy.</li><li>The company says it and its collaboration partner (Eli Lilly's Elanco Animal Health) will decide on whether to continue development after the latter reviews the data.</li><li>Shares are off&nbsp;<font color='red'>10%</font>&nbsp;after hours on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318728\" data-linked=\"Aratana&#39;s stem cell candidate AT-016 flunks osteoarthritis study in dogs, further development uncertain; shares down 10% after hours\" data-tweet=\"$PETX - Aratana&#39;s stem cell candidate AT-016 flunks osteoarthritis study in dogs, further development uncertain; shares down 10% after hours https://seekingalpha.com/news/3318728-aratanas-stem-cell-candidateminus-016-flunks-osteoarthritis-study-in-dogs-development?source=tweet\" data-url=\"https://seekingalpha.com/news/3318728-aratanas-stem-cell-candidateminus-016-flunks-osteoarthritis-study-in-dogs-development\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318724\" data-ts=\"1513372816\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKAM\" target=\"_blank\">AKAM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318724-akamaiplus-10_7-after-active-stake-reveal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akamai +10.7% after active stake reveal</a></h4><ul><li>        Elliott Associates <a href=\"http://www.ir.akamai.com/phoenix.zhtml?c=75943&amp;p=irol-sec#15341057\" target=\"_blank\">discloses</a> a 6.5% active stake in Akamai Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AKAM' title='Akamai Technologies, Inc.'>AKAM</a>).</li><li>               Akamai shares are&nbsp;<font color='green'>up 10.7%</font>&nbsp;aftermarket.&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3318724\" data-linked=\"Akamai +10.7% after active stake reveal\" data-tweet=\"$AKAM - Akamai +10.7% after active stake reveal https://seekingalpha.com/news/3318724-akamaiplus-10_7-after-active-stake-reveal?source=tweet\" data-url=\"https://seekingalpha.com/news/3318724-akamaiplus-10_7-after-active-stake-reveal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318715\" data-ts=\"1513372218\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RPRX\" target=\"_blank\">RPRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318715-prospects-dim-for-european-approval-of-repros-enclomiphene-for-secondary-hypogonadism-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Prospects dim for European approval of Repros&#39; enclomiphene for secondary hypogonadism; shares down 10% after hours</a></h4><ul><li>Repros Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RPRX' title='Repros Therapeutics Inc.'>RPRX</a>) <a href=\"https://seekingalpha.com/pr/17028582-repros-therapeutics-inc-receives-feedback-following-oral-explanation-european-medicines\" target=\"_blank\">announces</a> that the European Medicines Agency's advisory group, the Committee for Medicinal Products for Human Use &#40;CHMP&#41;, will likely adopt a negative opinion next month in response to its marketing application seeking approval for enclomiphene for the treatment of secondary hypogonadism.</li><li>Enclomiphene is one of two products in the company's pipeline (Proellex) so the news is a big negative for acquirer Allergan (NYSE:<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>).</li><li>Shares are off&nbsp;<font color='red'>10%</font>&nbsp;after hours on robust volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3212527-repros-marketing-application-enclomiphene-accepted-review-europe\" target=\"_blank\">Repros' marketing application for enclomiphene accepted for review in Europe</a> (Oct. 5, 2016)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317676-allergan-acquire-repros-0_67-per-share\" target=\"_blank\">Allergan to acquire Repros for $0.67 per share</a> (Dec. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318715\" data-linked=\"Prospects dim for European approval of Repros&#39; enclomiphene for secondary hypogonadism; shares down 10% after hours\" data-tweet=\"$RPRX $RPRX $AGN - Prospects dim for European approval of Repros&#39; enclomiphene for secondary hypogonadism; shares down 10% after hours https://seekingalpha.com/news/3318715-prospects-dim-for-european-approval-of-repros-enclomiphene-for-secondary-hypogonadism-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3318715-prospects-dim-for-european-approval-of-repros-enclomiphene-for-secondary-hypogonadism-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318711\" data-ts=\"1513372137\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPB\" target=\"_blank\">CPB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318711-snyders-lance-jumps-on-report-campbell-takeover-talks-are-advanced\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snyder&#39;s-Lance jumps on report Campbell takeover talks are advanced</a></h4><ul>   <li>Campbell Soup (NYSE:<a href='https://seekingalpha.com/symbol/CPB' title='Campbell Soup Company'>CPB</a>) is in <a href=\"https://www.cnbc.com/2017/12/15/campbell-soup-in-advanced-talks-to-acquire-snyders-lance.html\" target=\"_blank\">advanced talks to take over</a> Snyder's-Lance (NASDAQ:<a href='https://seekingalpha.com/symbol/LNCE' title='Snyder&#39;s-Lance, Inc.'>LNCE</a>), CNBC says, and a deal could come as soon as next week.</li>    <li>Snyder's-Lance is <font color='green'>up 3.4%</font> after hours, after <font color='green'>gaining 5.3%</font> during today's regular session; Campbell is near-flat in late trading after <font color='green'>2.1% gains</font> today.</li>    <li>That deal could value Snyder's at $50/share, a source tells the network, vs. today's close of $46.79; the deal could yet get delayed or fall apart entirely.</li><li>Such a deal for Snyder's-Lance (market cap: $4.6B) would be Campbell's largest. It wrapped a $700M acquisition of broth/soup company Pacific Foods this month and bought Bolthouse Farms for $1.55B in 2012.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318378-snyders-lance-spikes-cnbc-report-campbell-interest\" target=\"_blank\">Snyder's-Lance spikes on CNBC report of Campbell interest</a> (Dec. 14 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317900-campbell-soup-expects-pacific-foods-help-drive-organic-growth\" target=\"_blank\">Campbell Soup expects Pacific Foods to help drive organic growth</a> (Dec. 12 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318711\" data-linked=\"Snyder&#39;s-Lance jumps on report Campbell takeover talks are advanced\" data-tweet=\"$CPB $CPB $LNCE - Snyder&#39;s-Lance jumps on report Campbell takeover talks are advanced https://seekingalpha.com/news/3318711-snyders-lance-jumps-on-report-campbell-takeover-talks-are-advanced?source=tweet\" data-url=\"https://seekingalpha.com/news/3318711-snyders-lance-jumps-on-report-campbell-takeover-talks-are-advanced\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318704\" data-ts=\"1513371556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPE\" target=\"_blank\">EPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318704-ep-energy-buys-eagle-ford-acreage-from-carrizo-sells-uinta-basin-holdings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EP Energy buys Eagle Ford acreage from Carrizo, sells Uinta Basin holdings</a></h4><ul>     <li>EP&nbsp;Energy (<a href='https://seekingalpha.com/symbol/EPE' title='EP Energy Corporation'>EPE</a> <font color='red'>-3.9%</font>) is sharply lower a day after saying it <a href=\"https://seekingalpha.com/pr/17027655-ep-energy-announces-agreements-acquisition-eagle-ford-acreage-divestiture-certain-altamont\" target=\"_blank\">acquired</a> producing properties and undeveloped acreage from existing Eagle Ford operating areas in south Texas from Carrizo Oil &amp; Gas for $245M; CRZO had not revealed the buyer when it first announced the sale <a href=\"https://seekingalpha.com/news/3317730-carrizo-oil-and-gas-sell-piece-eagle-ford-acreage-245m\" target=\"_blank\">on Tuesday</a>.</li>     <li>EPE said it acquired 24.5K net acres, a 26% expansion of its current Eagle Ford position, with 3,400 boe/day net production during Q3.</li>     <li>EPE also said it agreed to sell ~23.3K net acres in the Altamont area of the Uinta Basin, ~14% of the company's total acreage position, for $180M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318704\" data-linked=\"EP Energy buys Eagle Ford acreage from Carrizo, sells Uinta Basin holdings\" data-tweet=\"$EPE $EPEG - EP Energy buys Eagle Ford acreage from Carrizo, sells Uinta Basin holdings https://seekingalpha.com/news/3318704-ep-energy-buys-eagle-ford-acreage-from-carrizo-sells-uinta-basin-holdings?source=tweet\" data-url=\"https://seekingalpha.com/news/3318704-ep-energy-buys-eagle-ford-acreage-from-carrizo-sells-uinta-basin-holdings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318693\" data-ts=\"1513367702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318693-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:&nbsp;</b><a href='https://seekingalpha.com/symbol/FORM' title='FormFactor, Inc.'>FORM</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/SOFO' title='Sonic Foundry, Inc.'>OTC:SOFO</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/MTLS' title='Materialise NV'>MTLS</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/PXLW' title='Pixelworks, Inc.'>PXLW</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/RESN' title='Resonant'>RESN</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/OHGI' title='One Horizon Group, Inc.'>OHGI</a> <font color='red'>-29%</font>. <a href='https://seekingalpha.com/symbol/ELTK' title='Eltek Ltd.'>ELTK</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a> <font color='red'>-8%</font>. NQ <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318693\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$FORM $SOFO $MTLS - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3318693-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3318693-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318684\" data-ts=\"1513364522\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318684-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NGS' title='Natural Gas Services Group, Inc.'>NGS</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/UNVR' title='Univar'>UNVR</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SDR' title='SandRidge Mississippian Trust II'>SDR</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/EPE' title='EP Energy Corporation'>EPE</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SDT' title='SandRidge Mississippian Trust I'>SDT</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SNMX' title='Senomyx, Inc.'>SNMX</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318684\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$NGS $UNVR $SDR - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3318684-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3318684-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318677\" data-ts=\"1513362687\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PIXY\" target=\"_blank\">PIXY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318677-shiftpixy-skyrockets-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ShiftPixy skyrockets after earnings</a></h4><ul> <li>It's a nice little <font color='green'>91% jump</font> for ShiftPixy (NASDAQ:<a href='https://seekingalpha.com/symbol/PIXY' title='ShiftPixy'>PIXY</a>) after the company dazzled with its <a href=\"https://seekingalpha.com/pr/17027831-shiftpixy-inc-reports-fiscal-fourth-quarter-full-year-2017-results\" target=\"_blank\">FQ4</a> report.</li> <li>Gross billings were up 20% to $33.1M during the quarter and full-year billings were up 149% to $126.4M</li> <li>ShiftPixy expects gross billings to hit $40M in Q1 of 2018.</li> <li>ShiftPixy still trades well short of the 52-week high of $11.63.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318409-shiftpixy-reports-fy-results\" target=\"_blank\">ShiftPixy reports FY results</a> (Dec. 14)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318677\" data-linked=\"ShiftPixy skyrockets after earnings\" data-tweet=\"$PIXY - ShiftPixy skyrockets after earnings https://seekingalpha.com/news/3318677-shiftpixy-skyrockets-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3318677-shiftpixy-skyrockets-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318671\" data-ts=\"1513361021\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LVLT\" target=\"_blank\">LVLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318671-barclays-windstream-debt-challenges-expects-frontier-dividend-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays: Windstream has debt challenges; expects Frontier dividend cut</a></h4><ul>   <li>Debt issues (and maturities coming in 2020) mean Windstream (<a href=\"http://seekingalpha.com/symbol/WIN\" target=\"_blank\">WIN</a> <font color='red'>-2.1%</font>) faces the biggest predicament in its space, Barclays says in a note on the sector that starts the company at Underweight.</li>    <li>Analyst Amir Rozwadowski has set a $1.50 price target, implying 29% further downside from today's lower price.</li>    <li>Windstream has already cut its dividend; meanwhile, Rozwadowski says another dividend cut is next for Frontier Communications (<a href=\"http://seekingalpha.com/symbol/FTR\" target=\"_blank\">FTR</a> <font color='red'>-2%</font>), which it's also launching at Underweight, with a $7 price target (18% downside implied).</li>    <li>It had <a href=\"https://seekingalpha.com/news/3318597-centurylink-plus-1_1-percent-barclays-lifts-equal-weight\" target=\"_blank\">raised CenturyLink</a> (<a href=\"http://seekingalpha.com/symbol/CTL\" target=\"_blank\">CTL</a> <font color='green'>+3.1%</font>) to Equal Weight based on a safer dividend and EBITDA that will likely be steady after the Level 3 (NASDAQ:<a href='https://seekingalpha.com/symbol/LVLT' title='Level 3 Communications, Inc.'>LVLT</a>) acquisition closing. Price target on CTL stays at $16, vs. current price of $17.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318671\" data-linked=\"Barclays: Windstream has debt challenges; expects Frontier dividend cut\" data-tweet=\"$LVLT $LVLT $WINMQ - Barclays: Windstream has debt challenges; expects Frontier dividend cut https://seekingalpha.com/news/3318671-barclays-windstream-debt-challenges-expects-frontier-dividend-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3318671-barclays-windstream-debt-challenges-expects-frontier-dividend-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318665\" data-ts=\"1513360047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTGE\" target=\"_blank\">MTGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318665-mortgage-reits-rally-after-mtge-lifts-dividend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mortgage REITs rally after MTGE lifts dividend</a></h4><ul><li>With short rates on the rise and the yield curve flattening, many are expecting lower earnings and then dividend cuts for the mortgage REIT sector (<a href='https://seekingalpha.com/symbol/REM' title='iShares Mortgage Real Estate Capped ETF'>REM</a> <font color='green'>+1%</font>).</li><li>MTGE Investment (<a href='https://seekingalpha.com/symbol/MTGE' title='MTGE Investment Corp.'>MTGE</a> <font color='green'>+2.2%</font>) - trading at a sizable discount to book value - last night may have surprised a few with <a href=\"https://seekingalpha.com/news/3318398-mtge-investment-declares-0_50-dividend\" target=\"_blank\">an 11% increase in</a> its quarterly payout. MTGE, however, is a non-agency player, and thus less dependent on the structure of interest rates than pure-agency REITs such as its cousin, AGNC Investment (<a href='https://seekingalpha.com/symbol/AGNC' title='AGNC Investment Corp.'>AGNC</a> <font color='green'>+1%</font>).</li><li>Nevertheless, the entire mREIT sector - agency and non-agency - is lit up green this session. Others: Annaly (<a href='https://seekingalpha.com/symbol/NLY' title='Annaly Capital Management, Inc.'>NLY</a> <font color='green'>+0.7%</font>), Armour (<a href='https://seekingalpha.com/symbol/ARR' title='ARMOUR Residential REIT, Inc.'>ARR</a> <font color='green'>+1.6%</font>), Two Harbors (<a href='https://seekingalpha.com/symbol/TWO' title='Two Harbors Investment Corp.'>TWO</a> <font color='green'>+1.5%</font>). Chimera (<a href='https://seekingalpha.com/symbol/CIM' title='Chimera Investment Corporation'>CIM</a> <font color='green'>+1.4%</font>), CYS (<a href='https://seekingalpha.com/symbol/CYS' title='CYS Investments, Inc.'>CYS</a> <font color='green'>+1.2%</font>), Invesco (<a href='https://seekingalpha.com/symbol/IVR' title='Invesco Mortgage Capital Inc.'>IVR</a> <font color='green'>+1.9%</font>), New York Mortgage (<a href='https://seekingalpha.com/symbol/NYMT' title='New York Mortgage Trust, Inc.'>NYMT</a>&nbsp;<font color='green'>+1.5%</font>),&nbsp;Western Asset (<a href='https://seekingalpha.com/symbol/WMC' title='Western Asset Mortgage Capital Corporation'>WMC</a> <font color='green'>+2%</font>), Anworth (<a href='https://seekingalpha.com/symbol/ANH' title='Anworth Mortgage Asset Corporation'>ANH</a> <font color='green'>+1.1%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/MORL' title='UBS ETRACS Monthly Pay 2x Leveraged Mortgage REIT ETN'>MORL</a>, <a href='https://seekingalpha.com/symbol/REM' title='iShares Mortgage Real Estate Capped ETF'>REM</a>, <a href='https://seekingalpha.com/symbol/MORT' title='VanEck Vectors Mortgage REIT Income ETF'>MORT</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3318665\" data-linked=\"Mortgage REITs rally after MTGE lifts dividend\" data-tweet=\"$MTGE $REM $MTGE - Mortgage REITs rally after MTGE lifts dividend https://seekingalpha.com/news/3318665-mortgage-reits-rally-after-mtge-lifts-dividend?source=tweet\" data-url=\"https://seekingalpha.com/news/3318665-mortgage-reits-rally-after-mtge-lifts-dividend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318664\" data-ts=\"1513359841\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYNA\" target=\"_blank\">SYNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318664-forbes-reveals-oem-using-synaptics-in-display-sensor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Forbes reveals OEM using Synaptics&#39; in-display sensor</a></h4><ul><li>        Synaptics (NASDAQ:<a href='https://seekingalpha.com/symbol/SYNA' title='Synaptics Incorporated'>SYNA</a>) recently announced that its in-display fingerprint sensors were in mass production for at top 5 OEM. Forbes&rsquo; Patrick Moorhead <a href=\"https://www.forbes.com/sites/patrickmoorhead/2017/12/14/synaptics-shipping-first-in-display-smartphone-fingerprint-reader-to-vivo/#71ac1eb832f4\" target=\"_blank\">reveals</a> that the OEM is Vivo.</li><li>               Moorehead saw a pre-production phone with the tech and said the sensor was &ldquo;fast and simple.&rdquo;&nbsp;</li><li>                  Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) has also worked on an in-display sensor that Vivo demoed earlier this year, but the switch to Synaptics suggests the Qualcomm version fell short on speed.    </li><li>               Embedding fingerprint sensors in displays has proven tricky and was why the Apple iPhone X lacked Touch ID in its OLED display.&nbsp;</li><li>               Synaptics shares are&nbsp;<font color='green'>up 0.7%</font>.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317846-synaptics-enters-mass-production-display-fingerprint-sensor\" target=\"_blank\">Synaptics enters mass production for in-display fingerprint sensor</a> (Dec. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318664\" data-linked=\"Forbes reveals OEM using Synaptics&#39; in-display sensor\" data-tweet=\"$SYNA $SYNA $QCOM - Forbes reveals OEM using Synaptics&#39; in-display sensor https://seekingalpha.com/news/3318664-forbes-reveals-oem-using-synaptics-in-display-sensor?source=tweet\" data-url=\"https://seekingalpha.com/news/3318664-forbes-reveals-oem-using-synaptics-in-display-sensor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318662\" data-ts=\"1513359664\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318662-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PIXY' title='ShiftPixy'>PIXY</a> <font color='green'>+86%</font>. <a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/EDUC' title='Educational Development Corporation'>EDUC</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/UUU' title='Universal Security Instruments, Inc'>UUU</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/PYDS' title='Payment Data Systems, Inc.'>PYDS</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CROX' title='Crocs, Inc.'>CROX</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/SGRY' title='Surgery Partners, Inc.'>SGRY</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/OHGI' title='One Horizon Group, Inc.'>OHGI</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/NYRT' title='New York REIT'>NYRT</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/OHRP' title='Ohr Pharmaceutical, Inc.'>OHRP</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CCCR-OLD' title='China Commercial Credit'>CCCR-OLD</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/NEWA' title='Newater Technology, Inc.'>NEWA</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CUR' title='Neuralstem, Inc.'>CUR</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318662\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$PIXY $ZCOR $SSC-OLD - Midday Gainers / Losers https://seekingalpha.com/news/3318662-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3318662-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318661\" data-ts=\"1513358736\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIRI\" target=\"_blank\">SIRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318661-sirius-xm-says-royalty-hike-may-be-material-evaluating-pricing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sirius XM says royalty hike may be material; it&#39;s evaluating pricing</a></h4><ul>   <li>An <a href=\"https://www.sec.gov/Archives/edgar/data/908937/000090893717000043/siri-20171215.htm\" target=\"_blank\">SEC filing</a> by Sirius XM (<a href=\"http://seekingalpha.com/symbol/SIRI\" target=\"_blank\">SIRI</a> <font color='red'>-6.8%</font>) indicates that the company is going to look at pricing changes after a royalty determination that it says could be material to results.</li>    <li>Yesterday the Copyright Royalty Board ruled on the company's statutory license payments for 2018-2022, determining the rate to be paid was 15.5% of gross revenues -- higher than the 11% for 2017.</li>    <li>Revenues subject to royalty include subscription revenues from digital audio radio subscribers, and advertising revenue from channels other than ones that only incidentally use sound performances. Other revenues are excluded from the statutory license fee.</li>    <li>\"We are in the process of studying and evaluating the rates and terms announced by the Copyright Royalty Board,\" the company says in the filing. \"We also expect to evaluate changes in our pricing, including the amount of our U.S. Music Royalty Fee.\"</li>    <li>\"We anticipate that the decision will result in an increase in our aggregate royalty expense on an annual basis beginning in 2018. We are not yet able to estimate the impact on our financial statements, although the additional royalty expense could be material.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318661\" data-linked=\"Sirius XM says royalty hike may be material; it&#39;s evaluating pricing\" data-tweet=\"$SIRI - Sirius XM says royalty hike may be material; it&#39;s evaluating pricing https://seekingalpha.com/news/3318661-sirius-xm-says-royalty-hike-may-be-material-evaluating-pricing?source=tweet\" data-url=\"https://seekingalpha.com/news/3318661-sirius-xm-says-royalty-hike-may-be-material-evaluating-pricing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318659\" data-ts=\"1513358304\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LFIN\" target=\"_blank\">LFIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318659-longfin-latest-name-to-boom-on-blockchain\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LongFin latest name to boom on blockchain</a></h4><ul>     <li>Just-public LongFin (<a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a>) this morning announced the acquisition of Ziddu.com - \"a blockchain-empowered solutions provider offering microfinance lending against collateralized warehouse receipts in the form of Ziddu Coins.\"</li><li>Shares have more than tripled today, currently&nbsp;<font color='green'>up 214%&nbsp;</font>to $16.90.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17028221-b-longfin-b-corp-acquires-ziddu-com-blockchain-empowered-global-micro-lending-solutions\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3318659\" data-linked=\"LongFin latest name to boom on blockchain\" data-tweet=\"$LFIN - LongFin latest name to boom on blockchain https://seekingalpha.com/news/3318659-longfin-latest-name-to-boom-on-blockchain?source=tweet\" data-url=\"https://seekingalpha.com/news/3318659-longfin-latest-name-to-boom-on-blockchain\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318655\" data-ts=\"1513357331\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IGXT\" target=\"_blank\">IGXT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318655-intelgenx-on-go-in-canada-to-launch-mid-stage-study-of-montelukast-versafilm-in-alzheimers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IntelGenx on go in Canada to launch mid-stage study of Montelukast VersaFilm in Alzheimer&#39;s; shares ahead 5%</a></h4><ul><li>Health Canada <a href=\"https://seekingalpha.com/pr/17028186-intelgenx-receives-health-canada-clearance-begin-phase-2a-study-montelukast-versafilm-tm-mild\" target=\"_blank\">has signed</a> off on a Phase 2a proof-of-concept study assessing IntelGenx's (<a href='https://seekingalpha.com/symbol/IGXT' title='IntelGenx Technologies Corp.'>OTCQX:IGXT</a> <font color='green'>+4.6%</font>) Montelukast VersaFilm in patients with mild-to-moderate Alzheimer's disease &#40;AD&#41;. Patient screening should commence next quarter.</li><li>The 70-subject, randomized, double-blind, placebo-controlled trial will evaluate the safety, feasibility, tolerability and efficacy of Montelukast buccal film over a 26-week treatment period.</li><li>The company says it is repositioning Montelukast as a treatment for neurodegenerative diseases by reformulating it into an oral film-based product. It was approved in the U.S. in 1997 in a tablet formulation to treat asthma and allergic rhinitis.</li><li>Montelukast, marketed as <a href=\"https://www.merck.com/product/usa/pi_circulars/s/singulair/singulair.html\" target=\"_blank\">SINGULAIR </a>by Merck, is a leukotriene receptor antagonist. Specifically, it binds to receptors to a family of pro-inflammatory lipid mediators called <a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1569601/\" target=\"_blank\">cysteinyl leukotrienes</a>. Blocking their activation inhibits the inflammatory cascade that causes the symptoms of asthma and allergic rhinitis.</li><li>The product may have potential in treating AD because neuro-inflammation is believed to be a cause of dementia.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318655\" data-linked=\"IntelGenx on go in Canada to launch mid-stage study of Montelukast VersaFilm in Alzheimer&#39;s; shares ahead 5%\" data-tweet=\"$IGXT - IntelGenx on go in Canada to launch mid-stage study of Montelukast VersaFilm in Alzheimer&#39;s; shares ahead 5% https://seekingalpha.com/news/3318655-intelgenx-on-go-in-canada-to-launch-mid-stage-study-of-montelukast-versafilm-in-alzheimers?source=tweet\" data-url=\"https://seekingalpha.com/news/3318655-intelgenx-on-go-in-canada-to-launch-mid-stage-study-of-montelukast-versafilm-in-alzheimers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318654\" data-ts=\"1513357209\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318654-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CROX' title='Crocs, Inc.'>CROX</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/UA' title='Under Armour, Inc. Class C'>UA</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/SENEA' title='Seneca Foods Corp.'>SENEA</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/DLA' title='Delta Apparel, Inc'>DLA</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/LNCE' title='Snyder&#39;s-Lance, Inc.'>LNCE</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/FORD' title='Forward Industries, Inc.'>FORD</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318654\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$CROX $UA $SENEA - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3318654-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3318654-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318649\" data-ts=\"1513356385\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318649-keybanc-downgrades-fox-amid-high-regulatory-risk-around-disney-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KeyBanc downgrades Fox amid high regulatory risk around Disney deal</a></h4><ul>   <li>A day after their sector-shaking $52.4B deal over assets, Walt Disney (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>) is <font color='green'>up another 0.5%</font>, while Twenty-First Century Fox is significantly higher as well (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='green'>+2.2%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='green'>+1.9%</font>).</li>    <li>While the deal looks positive for both sides, it comes with high antitrust risk, says KeyBanc analyst Andy Hargreaves in a note downgraded Fox to Sector Weight.</li>    <li>The antitrust environment (which also features government opposition of the $85B AT&amp;T/Time Warner deal) is \"highly uncertain,\" Hargreaves says, and that means a discount is warranted.</li>    <li>Opposition to the Fox/Disney deal may not just come from competitors but also from sports leagues, facing the combination of ESPN with Fox's 22 regional sports networks.</li>    <li>Meanwhile, he says the news leaves Viacom (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color='green'>+1%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color='green'>+0.8%</font>) and Lions Gate (<a href='https://seekingalpha.com/symbol/LGF.A' title='Lions Gate Entertainment Corp.'>LGF.A</a> <font color='green'>+1%</font>, <a href='https://seekingalpha.com/symbol/LGF.B' title='Lions Gate Entertainment Corp.'>LGF.B</a> <font color='green'>+0.8%</font>) as the most attractive candidates for acquisition among traditional media. (h/t Bloomberg)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318649\" data-linked=\"KeyBanc downgrades Fox amid high regulatory risk around Disney deal\" data-tweet=\"$DIS $DIS $FOX - KeyBanc downgrades Fox amid high regulatory risk around Disney deal https://seekingalpha.com/news/3318649-keybanc-downgrades-fox-amid-high-regulatory-risk-around-disney-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3318649-keybanc-downgrades-fox-amid-high-regulatory-risk-around-disney-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318648\" data-ts=\"1513356326\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVE\" target=\"_blank\">CVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318648-cenovusminus-8-in-two-days-after-job-cuts-below-guidance-production-view\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cenovus -8% in two days after job cuts, below guidance production view</a></h4><ul>     <li>Cenovus Energy (<a href='https://seekingalpha.com/symbol/CVE' title='Cenovus Energy, Inc.'>CVE</a> <font color='red'>-2.3%</font>), which has been selling assets to pay off debt from its $13B oil sands acquisition earlier this year, plans to <a href=\"https://seekingalpha.com/pr/17026796-cenovus-s-2018-budget-continues-focus-deleveraging\" target=\"_blank\">cut ~15% of its total workforce</a>, or 500-700 jobs, as new CEO&nbsp;Alex Pourbaix steps up cost cuts.</li>     <li>CFO&nbsp;Ivor Ruste will leave the company in April, Upstream Oil &amp;&nbsp;Gas chief Kieron McFadyen will depart in January, and Downstream president and U.S. operations director Bob Pease also will leave in January.</li>     <li>The announcements were part of CVE&rsquo;s 2018 budget report, which detailed a $1.5B-$1.7B capital spending program and a 2018 oil production forecast of 483K-510K boe/day that trailed some analysts&rsquo; expectations.</li>     <li>The company's new CEO is \"laying the ground work for a better day, and we anticipate more updates will come over the next few months as management gains its footing,\" says Desjardins analyst Justin Bouchard. &ldquo;The <a href=\"https://www.bloomberg.com/news/articles/2017-12-14/cenovus-energy-plans-to-cut-15-of-workers-reshuffle-management\" target=\"_blank\">new budget is positive</a> in that it sends a clear message regarding capital discipline, particularly for a company facing numerous headwinds.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3318648\" data-linked=\"Cenovus -8% in two days after job cuts, below guidance production view\" data-tweet=\"$CVE - Cenovus -8% in two days after job cuts, below guidance production view https://seekingalpha.com/news/3318648-cenovusminus-8-in-two-days-after-job-cuts-below-guidance-production-view?source=tweet\" data-url=\"https://seekingalpha.com/news/3318648-cenovusminus-8-in-two-days-after-job-cuts-below-guidance-production-view\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318646\" data-ts=\"1513356227\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADBE\" target=\"_blank\">ADBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318646-pivotal-research-group-ups-adobes-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pivotal Research Group ups Adobe&#39;s price target</a></h4><ul><li>        Pivotal Research Group <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171215112247ADBE\" target=\"_blank\">raises</a> its Adobe Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a>) price target by $2 to $162 and maintains its Hold position.</li><li>                  The firm cites the positive earnings report yesterday and favorable FY18 outlook.    </li><li>               Adobe Systems shares are&nbsp;<font color='green'>up 1.3%</font>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318451-adobe-systems-plus-1_6-percent-q4-beats-positive-q1-fy18-guidance\" target=\"_blank\">Adobe Systems +1.6% on Q4 beats, positive Q1 and FY18 guidance</a> (Dec. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318646\" data-linked=\"Pivotal Research Group ups Adobe&#39;s price target\" data-tweet=\"$ADBE - Pivotal Research Group ups Adobe&#39;s price target https://seekingalpha.com/news/3318646-pivotal-research-group-ups-adobes-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3318646-pivotal-research-group-ups-adobes-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318640\" data-ts=\"1513355074\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HBI\" target=\"_blank\">HBI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318640-hanesbrands-scores-better-credit-facility-terms\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HanesBrands scores better credit facility terms</a></h4><ul>          <li>HanesBrands (NYSE:<a href='https://seekingalpha.com/symbol/HBI' title='Hanesbrands Inc.'>HBI</a>) announces changes to its senior secured credit facility that it says will help the company&rsquo;s long-term       global growth and capital allocation strategies.</li>     <li>The credit facility changes include lower interest rates, higher capacity and increased flexibility.</li>     <li>By the numbers: The HanesBrands enior secured credit facility is increased to $2.25B from       $1.925B. The interest rates of the revolver and Term Loan A are decreased 25 bps points, while the rate for the Term Loan B is dropped by 75 bps.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17028360-hanesbrands-favorably-amends-senior-secured-credit-facility\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3318640\" data-linked=\"HanesBrands scores better credit facility terms\" data-tweet=\"$HBI - HanesBrands scores better credit facility terms https://seekingalpha.com/news/3318640-hanesbrands-scores-better-credit-facility-terms?source=tweet\" data-url=\"https://seekingalpha.com/news/3318640-hanesbrands-scores-better-credit-facility-terms\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318635\" data-ts=\"1513354022\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SKX\" target=\"_blank\">SKX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318635-rally-time-for-skechers-after-argus-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rally time for Skechers after Argus boost</a></h4><ul> <li>Argus upgrades Skechers (<a href='https://seekingalpha.com/symbol/SKX' title='Skechers USA Inc.'>SKX</a> <font color='green'>+3.4%</font>) to a Buy rating off of higher EPS estimates for 2017 and 2018.</li> <li>\"We believe a recovery in the company's domestic wholesale business is underway. While wholesale revenue in the U.S. was up just 1.4% in 3Q17, we believe it will improve driven by an improvement in U.S. retail comps,\" writes lead analyst John Staszak.</li> <li>Staszak is bullish even beyond the one-year time frame. \"We expect Skechers to continue to develop innovative products and to expand through new store openings and international distribution agreements. We also expect the company to benefit from rapid growth in emerging markets, especially China and India,\" he predicts.</li> <li>Source: Analyst note</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318635\" data-linked=\"Rally time for Skechers after Argus boost\" data-tweet=\"$SKX - Rally time for Skechers after Argus boost https://seekingalpha.com/news/3318635-rally-time-for-skechers-after-argus-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3318635-rally-time-for-skechers-after-argus-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318603\" data-ts=\"1513353771\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318603-healthcare-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/CGEN' title='Compugen Ltd.'>CGEN</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/SGRY' title='Surgery Partners, Inc.'>SGRY</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/OHRP' title='Ohr Pharmaceutical, Inc.'>OHRP</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/STML' title='Stemline Therapeutics'>STML</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/CUR' title='Neuralstem, Inc.'>CUR</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318603\" data-linked=\"Healthcare Gainers / Losers as of 11:00 am\" data-tweet=\"$ZCOR $CGEN $RIOT - Healthcare Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3318603-healthcare-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3318603-healthcare-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318629\" data-ts=\"1513353060\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318629-tax-bill-is-back-to-go-stocks-rise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tax bill is back to a &#39;go&#39; - stocks rise</a></h4><ul><li>Florida Senator Marco Rubio yesterday suggested he was a \"no,\" but the child-care tax credit he was concerned about <a href=\"https://www.wsj.com/livecoverage/tax-bill-2017/card/1513352168\" target=\"_blank\">has reportedly been lifted </a>to $1.4K from $1.1K.</li><li>Fox News is now reporting Rubio as a \"yes.\"</li><li>Meanwhile, House Ways &amp; Means head Kevin Brady says the bill is done, and hopes for broad Senate support.</li><li>Stocks are near session highs, the S&amp;P 500&nbsp;<font color='green'>up 0.65%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318629\" data-linked=\"Tax bill is back to a &#39;go&#39; - stocks rise\" data-tweet=\"Tax bill is back to a &#39;go&#39; - stocks rise https://seekingalpha.com/news/3318629-tax-bill-is-back-to-go-stocks-rise?source=tweet\" data-url=\"https://seekingalpha.com/news/3318629-tax-bill-is-back-to-go-stocks-rise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318626\" data-ts=\"1513352518\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLY\" target=\"_blank\">LLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318626-european-advisory-group-backs-lillys-taltz-for-psoriatic-arthritis-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory group backs Lilly&#39;s Taltz for psoriatic arthritis; shares up 1%</a></h4><ul><li>The European Medicines Agency's Committee for Medicinal Products for Human Use &#40;CHMP&#41; adopts a <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003943/smops/Positive/human_smop_001239.jsp&amp;mid=WC0b01ac058001d127\" target=\"_blank\">positive opinion</a> recommending approval for Eli Lilly's (<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color='green'>+0.9%</font>) Taltz (ixekizumab) for the treatment of adult patients with psoriatic arthritis, either as monotherapy or with methotrexate, who have failed to respond adequately to previous therapies (DMARDs).</li><li>A final decision from the European Commission usually takes ~60 days.</li><li>Taltz was approved in the U.S. for the indication earlier this month. It was approved in the EU and U.S. for plaque psoriasis in 2016.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318626\" data-linked=\"European advisory group backs Lilly&#39;s Taltz for psoriatic arthritis; shares up 1%\" data-tweet=\"$LLY - European advisory group backs Lilly&#39;s Taltz for psoriatic arthritis; shares up 1% https://seekingalpha.com/news/3318626-european-advisory-group-backs-lillys-taltz-for-psoriatic-arthritis-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3318626-european-advisory-group-backs-lillys-taltz-for-psoriatic-arthritis-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318620\" data-ts=\"1513351760\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYL\" target=\"_blank\">MYL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318620-european-advisory-group-backs-mylans-generic-xagrid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory group backs Mylan&#39;s generic Xagrid</a></h4><ul><li>The European Medicines Agency's Committee for Medicinal Products for Human Use &#40;CHMP&#41; <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004585/smops/Positive/human_smop_001240.jsp&amp;mid=WC0b01ac058001d127\" target=\"_blank\">recommends </a>approval for Mylan NV's (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='green'>+1.1%</font>) generic version of Shire's <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000480/WC500056557.pdf\" target=\"_blank\">Xagrid </a>(anagrelide hydrochloride), indicated for the treatment of elevated blood platelets in at-risk patients with <a href=\"http://www.merckmanuals.com/home/blood-disorders/myeloproliferative-disorders/thrombocythemia\" target=\"_blank\">thrombocythemia </a>(abnormally high platelets).</li><li>A final decision from the European Commission usually takes ~60 days.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318620\" data-linked=\"European advisory group backs Mylan&#39;s generic Xagrid\" data-tweet=\"$MYL - European advisory group backs Mylan&#39;s generic Xagrid https://seekingalpha.com/news/3318620-european-advisory-group-backs-mylans-generic-xagrid?source=tweet\" data-url=\"https://seekingalpha.com/news/3318620-european-advisory-group-backs-mylans-generic-xagrid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318618\" data-ts=\"1513351547\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BT\" target=\"_blank\">BT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318618-uks-bt-sky-to-offer-others-channels\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UK&#39;s BT, Sky to offer each other&#39;s channels</a></h4><ul>   <li>UK TV providers BT (<a href=\"http://seekingalpha.com/symbol/BT\" target=\"_blank\">BT</a> <font color='green'>+0.1%</font>) and Sky (<a href=\"http://seekingalpha.com/symbol/SKYAY\" target=\"_blank\">SKYAY</a> <font color='green'>+1.7%</font>) have taken a minor step to thaw their rivalry with an <a href=\"https://www.reuters.com/article/us-bt-sky/bt-and-sky-strike-deal-to-carry-each-others-channels-idUSKBN1E90K8?feedType=nl&amp;feedName=innovationNews&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=US%20Deals%20Today%202017-12-15&amp;utm_term=US%20Deals%20Today\" target=\"_blank\">agreement to carry each other's most popular channels</a>.</li>    <li>BT customers will be able to sign up for Sky's NOW TV, which boasts Premier League matches and shows like Game of Thrones, while Sky satellite customers will get access to heavy sports content from BT, including Champions League soccer, 42 Premier League games and Ashes cricket.</li>    <li>Notably for costs, the two companies had paid &pound;5.14B combined for Premier League rights on the last go-round, a 70% increase from the previous deal.</li>    <li>The reciprocal agreement is set to start early 2019. The move comes amid almost weekly changes to the TV landscape, and a shift in competition from new digital players like Amazon.com and Netflix.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318618\" data-linked=\"UK&#39;s BT, Sky to offer each other&#39;s channels\" data-tweet=\"$BT $BT $SKYAY - UK&#39;s BT, Sky to offer each other&#39;s channels https://seekingalpha.com/news/3318618-uks-bt-sky-to-offer-others-channels?source=tweet\" data-url=\"https://seekingalpha.com/news/3318618-uks-bt-sky-to-offer-others-channels\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318611\" data-ts=\"1513350224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MET\" target=\"_blank\">MET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318611-metlife-down-2-on-disappointing-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MetLife down 2% on disappointing outlook</a></h4><ul><li>The company this morning hosted a call to discuss its 2018 outlook.</li><li><a href=\"http://investor.metlife.com/phoenix.zhtml?c=121171&amp;p=irol-presentations\" target=\"_blank\">Webcast and presentation slides</a></li><li>A few notable items: In the Retirement and Income Solutions business, management expects investment income spread of 110-135 basis points down from 145 in 2017.</li><li>In P&amp;C, the overall combined ratio is seen at 100% over the last 12 months vs. the long-term target of 92-97%.</li><li>In Asia, its about emerging markets, with robust double-digit sales growth expected in 2018.</li><li>In EMEA, the exit from the U.K. retirement market is expected to leave sales growth in the mid-single digits, but then low double-digit growth. Dividends to the holding companies are seen topping operating earnings.</li><li>The company's variable investment income range is seen at $800M-$1B pretax next year. Expense initiative costs are expected to be about $330M. Liability management of $2B-$3B in 2017-18, up from $1B-$2B.</li><li>There's not much word yet out from the sell-side, but one report has Goldman calling the guidance disappointing.</li><li><a href='https://seekingalpha.com/symbol/MET' title='MetLife, Inc.'>MET</a>&nbsp;<font color='red'>-2.2%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3318611\" data-linked=\"MetLife down 2% on disappointing outlook\" data-tweet=\"$MET - MetLife down 2% on disappointing outlook https://seekingalpha.com/news/3318611-metlife-down-2-on-disappointing-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3318611-metlife-down-2-on-disappointing-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318608\" data-ts=\"1513349960\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBT\" target=\"_blank\">GBT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318608-global-blood-executes-100m-market-stock-offering-shares-down-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Global Blood executes $100M at-the-market stock offering; shares down 6%</a></h4><ul><li>Global Blood Therapeutics (<a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a> <font color='red'>-5.5%</font>) <a href=\"https://seekingalpha.com/pr/17028305-global-blood-therapeutics-prices-100_0-million-common-stock-public-offering\" target=\"_blank\">prices </a>its $100M public offering of common stock at the market. Yesterday's close was $39.40.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318608\" data-linked=\"Global Blood executes $100M at-the-market stock offering; shares down 6%\" data-tweet=\"$GBT - Global Blood executes $100M at-the-market stock offering; shares down 6% https://seekingalpha.com/news/3318608-global-blood-executes-100m-market-stock-offering-shares-down-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3318608-global-blood-executes-100m-market-stock-offering-shares-down-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318605\" data-ts=\"1513349398\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318605-teva-launches-generic-tdf-in-u-s\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva launches generic TDF in U.S.</a></h4><ul><li>Teva Pharmaceutical Industries (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='green'>+2.1%</font>) <a href=\"https://seekingalpha.com/pr/17028260-teva-announces-exclusive-launch-generic-viread-united-states\" target=\"_blank\">announces </a>the U.S. commercial launch of its version of tenofovir disoproxil fumarate &#40;TDF&#41; for the treatment of HIV-1 infection in patients at least two years old and chronic hepatitis B virus &#40;HBV&#41; infection in patients at least 12 years old.</li><li>In the first three calendar quarters of 2017, Gilead Sciences' TDF, branded as Viread, generated $375M in U.S. sales, down 6% yoy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318605\" data-linked=\"Teva launches generic TDF in U.S.\" data-tweet=\"$TEVA - Teva launches generic TDF in U.S. https://seekingalpha.com/news/3318605-teva-launches-generic-tdf-in-u-s?source=tweet\" data-url=\"https://seekingalpha.com/news/3318605-teva-launches-generic-tdf-in-u-s\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318604\" data-ts=\"1513349333\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRTO\" target=\"_blank\">CRTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318604-criteominus-2_3-analysts-process-apple-feature-news-impact\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Criteo -2.3% as analysts process Apple feature news impact</a></h4><ul>   <li>Criteo (NASDAQ:<a href='https://seekingalpha.com/symbol/CRTO' title='Criteo S.A.'>CRTO</a>) is <font color='red'>2.3% lower</font> in continuing fallout from Apple's Intelligent Tracking Prevention and the <a href=\"https://seekingalpha.com/news/3318281-criteo-minus-12_4-percent-expected-impact-apple-change\" target=\"_blank\">anticipated effects it will have</a> on the company's super cookie.</li>    <li>Citi and JMP have downgraded shares to Neutral equivalent, and Jefferies trimmed its price target to $28.</li>    <li>SunTrust has cut its price target to $35, and Stifel has gone further, down to $26 from $40. But Stifel says at current levels the company's more likely to attract strategic buyers in the ad tech space. It expects 2018 revenue ex-TAC to be $935M rather than $1.02B.</li>    <li>But Macquarie is flying in the face of negativity with an upgrade to Outperform, suggesting the worst case has become the base case and recalibrating expectations accordingly. It's got a lowered price target of $30, impying 26% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318604\" data-linked=\"Criteo -2.3% as analysts process Apple feature news impact\" data-tweet=\"$CRTO - Criteo -2.3% as analysts process Apple feature news impact https://seekingalpha.com/news/3318604-criteominus-2_3-analysts-process-apple-feature-news-impact?source=tweet\" data-url=\"https://seekingalpha.com/news/3318604-criteominus-2_3-analysts-process-apple-feature-news-impact\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318599\" data-ts=\"1513348208\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UA\" target=\"_blank\">UA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318599-under-armour-bounces-after-stifel-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Under Armour bounces after Stifel upgrade</a></h4><ul> <li>Under Armour (<a href='https://seekingalpha.com/symbol/UA' title='Under Armour, Inc. Class C'>UA</a>, <a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a>) jumps in early trading after Stifel Nicolaus issues a strong endorsement of the upside potential for shares.</li> <li>The firm boosts UA to a Buy rating from Hold on its view that the athletic apparel giant's cost discipline is improved and sales growth is returning to form.</li> <li>The price target from Stifel on UAA&nbsp;is $17.</li> <li>Sources: CNBC and Nasdaq.com</li><li>UAA <font color='green'>+4.20%</font> premarket to $14.40.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318599\" data-linked=\"Under Armour bounces after Stifel upgrade\" data-tweet=\"$UA $UA $UAA - Under Armour bounces after Stifel upgrade https://seekingalpha.com/news/3318599-under-armour-bounces-after-stifel-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3318599-under-armour-bounces-after-stifel-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318598\" data-ts=\"1513348192\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSTM\" target=\"_blank\">VSTM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318598-verastem-down-13-premarket-on-pricing-of-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verastem down 13% premarket on pricing of stock offering</a></h4><ul><li>Verastem (NASDAQ:<a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a>) slumps&nbsp;<font color='red'>13%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/17028313-verastem-announces-pricing-public-offering-common-stock\" target=\"_blank\">public offering</a> of 8.4M shares of common stock at $3.07 per share.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318598\" data-linked=\"Verastem down 13% premarket on pricing of stock offering\" data-tweet=\"$VSTM - Verastem down 13% premarket on pricing of stock offering https://seekingalpha.com/news/3318598-verastem-down-13-premarket-on-pricing-of-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3318598-verastem-down-13-premarket-on-pricing-of-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318594\" data-ts=\"1513347888\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RARE\" target=\"_blank\">RARE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318594-european-advisory-group-backs-conditional-approval-for-ultragenyxs-burosumab-for-inherited\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory group backs conditional approval for Ultragenyx&#39;s burosumab for inherited form of rickets; shares up 1% premarket</a></h4><ul><li>The European Medicines Agency's Committee for Medicinal Products for Human Use &#40;CHMP&#41; adopts a <a href=\"https://seekingalpha.com/pr/17028217-ultragenyx-kyowa-kirin-announce-burosumab-receives-positive-chmp-opinion-treatment-x-linked\" target=\"_blank\">positive opinion</a> recommending conditional approval for Ultragenyx Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/RARE' title='Ultragenyx Pharmaceutical Inc.'>RARE</a>) and development partner Kyowa Kirin International's burosumab for the treatment of <a href=\"https://en.wikipedia.org/wiki/X-linked_hypophosphatemia\" target=\"_blank\">X-linked hypophosphatemia</a>, an inherited form of rickets in which sufferers do not benefit from ingesting vitamin D.</li><li>Kyowa will market the product under the brand name Crysvita.</li><li>Conditional status means that the approval is granted based on less comprehensive data than is normally required because the benefit of the medication is substantially greater than the risk. The sponsor will still be required to submit more data at some point.</li><li>A final decision from the European Commission usually takes ~60 days.</li><li>Burosumab is a recombinant fully human monoclonal IgG1 antibody that binds to FGF23, a hormone that reduces serum phosphorus and active vitamin D by regulating phosphate excretion and active vitamin D production by the kidney.</li><li>RARE's U.S. marketing application is currently under review with an action date of April 17, 2018.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket albeit on only 215 shares.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3306629-ad-com-review-planned-ultragenyx-bla-burosumab-xlh-action-date-april-2018-shares-3-percent\" target=\"_blank\">No Ad Com review planned for Ultragenyx BLA for burosumab for XLH, action date April 2018; shares up 3%</a> (Nov. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318594\" data-linked=\"European advisory group backs conditional approval for Ultragenyx&#39;s burosumab for inherited form of rickets; shares up 1% premarket\" data-tweet=\"$RARE - European advisory group backs conditional approval for Ultragenyx&#39;s burosumab for inherited form of rickets; shares up 1% premarket https://seekingalpha.com/news/3318594-european-advisory-group-backs-conditional-approval-for-ultragenyxs-burosumab-for-inherited?source=tweet\" data-url=\"https://seekingalpha.com/news/3318594-european-advisory-group-backs-conditional-approval-for-ultragenyxs-burosumab-for-inherited\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318589\" data-ts=\"1513347194\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318589-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul> <li><a href='https://seekingalpha.com/symbol/PIXY' title='ShiftPixy'>PIXY</a> <font color='green'>+118%</font> on FY earnings.</li><li><a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='green'>+39%</font>.</li><li><a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a> <font color='green'>+19%</font> on <a href=\"https://seekingalpha.com/news/3318525-fda-tentatively-oks-expanded-label-egalets-pain-med-arymo-er-shares-31-percent-premarket\" target=\"_blank\">tentative FDA approval</a> of ARYMO ER.</li><li><a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='green'>+11%</font> on <a href=\"https://seekingalpha.com/news/3318548-japanese-men-behind-bitcoin-surge-deutsche\" target=\"_blank\">bitcoin surge</a>.</li><li><a href='https://seekingalpha.com/symbol/SIEB' title='Siebert Financial Corp.'>SIEB</a> <font color='green'>+10%</font> on <a href=\"https://seekingalpha.com/news/3318367-siebert-financial-60-percent-crypto-trading-deal\" target=\"_blank\">crypto trading</a> deal.</li><li>DDR <font color='green'>+10%</font> on <a href=\"https://seekingalpha.com/news/3318433-ddr-spinning-non-core-malls\" target=\"_blank\">spinning off</a> non-core malls.</li><li><a href='https://seekingalpha.com/symbol/GLPG' title='Galapagos'>GLPG</a> <font color='green'>+9%</font> on  <a href=\"https://seekingalpha.com/news/3318578-galapagos-9-percent-premarket-decision-co-promote-filgotinib-europe\" target=\"_blank\">co-promoting filgotinib</a> with Gilead Sciences in eight European countries.</li><li><a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Ltd.'>GLBS</a> <font color='green'>+8%</font>.</li><li><a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a> <font color='green'>+7%</font> on <a href=\"https://seekingalpha.com/news/3318548-japanese-men-behind-bitcoin-surge-deutsche\" target=\"_blank\">bitcoin surge</a>.</li><li><a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a> <font color='green'>+6%</font> on <a href=\"https://seekingalpha.com/news/3318548-japanese-men-behind-bitcoin-surge-deutsche\" target=\"_blank\">bitcoin surge</a>.</li><li><a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color='green'>+5%</font> on <a href=\"https://seekingalpha.com/news/3318540-fda-lifts-clinical-hold-alnylams-fitusiran-shares-6-percent-premarket\" target=\"_blank\">FDA removal</a> of clinical hold on fitusiran.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3318589\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$PIXY $DCIX $ZCOR - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3318589-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3318589-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318588\" data-ts=\"1513347132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTR\" target=\"_blank\">FTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318588-frontier-communicationsminus-2_3-barclays-starts-underweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Frontier Communications -2.3% as Barclays starts at Underweight</a></h4><ul>   <li>Frontier Communications (NYSE:<a href='https://seekingalpha.com/symbol/FTR' title='Frontier Communications Corporation'>FTR</a>) is <font color='red'>2.3% lower</font> premarket after getting a new Underweight rating from Barclays.</li>    <li>The firm has set a below-average price target of $7, implying 19.4% downside.</li>    <li>Shares had <font color='red'>fallen 14.8%</font> yesterday but were trading ex-dividend after a $0.60 distribution. (On an adjusted basis, shares fell 9.5%).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318588\" data-linked=\"Frontier Communications -2.3% as Barclays starts at Underweight\" data-tweet=\"$FTR - Frontier Communications -2.3% as Barclays starts at Underweight https://seekingalpha.com/news/3318588-frontier-communicationsminus-2_3-barclays-starts-underweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3318588-frontier-communicationsminus-2_3-barclays-starts-underweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318586\" data-ts=\"1513346979\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318586-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/OHGI' title='One Horizon Group, Inc.'>OHGI</a> <font color='red'>-14%</font>.</li><li><a href='https://seekingalpha.com/symbol/CSX' title='CSX Corporation'>CSX</a>&nbsp;<font color='red'>-10%</font>&nbsp;on CEO Harrison <a href=\"https://seekingalpha.com/news/3318570-csx-falls-sharply-harrison-medical-leave\" target=\"_blank\">medical leave</a>.</li><li><a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a>&nbsp;<font color='red'>-10%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3318530-verastem-readies-equity-offering-shares-8-percent-premarket\" target=\"_blank\">announcing</a> public offering of common stock.</li><li><a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a>&nbsp;<font color='red'>-5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3318399-oracle-beats-0_02-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/GSAT' title='Globalstar, Inc.'>GSAT</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3318586\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$OHGI $CSX $VSTM - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3318586-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3318586-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318578\" data-ts=\"1513346429\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLPG\" target=\"_blank\">GLPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318578-galapagos-up-9-premarket-on-decision-to-co-promote-filgotinib-in-europe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galapagos up 9% premarket on decision to co-promote filgotinib in Europe</a></h4><ul><li>Galapagos NV (NASDAQ:<a href='https://seekingalpha.com/symbol/GLPG' title='Galapagos'>GLPG</a>) is up&nbsp;<font color='green'>9%</font>&nbsp;premarket on average volume after it decided to co-promote JAK1 inhibitor filgotinib with Gilead Sciences in eight European countries.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318416-galapagos-elects-co-promote-filgotinib-gilead-europe\" target=\"_blank\">Galapagos elects to co-promote filgotinib with Gilead in Europe</a> (Dec. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318578\" data-linked=\"Galapagos up 9% premarket on decision to co-promote filgotinib in Europe\" data-tweet=\"$GLPG - Galapagos up 9% premarket on decision to co-promote filgotinib in Europe https://seekingalpha.com/news/3318578-galapagos-up-9-premarket-on-decision-to-co-promote-filgotinib-in-europe?source=tweet\" data-url=\"https://seekingalpha.com/news/3318578-galapagos-up-9-premarket-on-decision-to-co-promote-filgotinib-in-europe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318576\" data-ts=\"1513346124\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FORM\" target=\"_blank\">FORM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318576-needham-upgrades-formfactor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham upgrades FormFactor</a></h4><ul><li>        Needham <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171215074047FORM\" target=\"_blank\">upgrades</a> FormFactor (NASDAQ:<a href='https://seekingalpha.com/symbol/FORM' title='FormFactor, Inc.'>FORM</a>) from Buy to Strong Buy and raises the price target by $2 to $22. The firm names FormFactor a Top Pick for next year.</li><li>               Firm cites solid demand expectations, gained market share in foundry/logic, and low expectations built into the conservative consensus estimates.&nbsp;</li><li>               Needham thinks FormFactor warrants a higher multiple even on the wrong side of a semi cycle. &nbsp;&nbsp;</li><li>               FormFactor shares are&nbsp;<font color='green'>up 2%</font>&nbsp;premarket.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3318576\" data-linked=\"Needham upgrades FormFactor\" data-tweet=\"$FORM - Needham upgrades FormFactor https://seekingalpha.com/news/3318576-needham-upgrades-formfactor?source=tweet\" data-url=\"https://seekingalpha.com/news/3318576-needham-upgrades-formfactor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318575\" data-ts=\"1513346087\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDUS\" target=\"_blank\">RDUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318575-radius-health-not-quite-european-marketing-application-for-osteoporosis-med-abaloparatide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Radius Health not quite there with European marketing application for osteoporosis med abaloparatide; shares down 3% premarket</a></h4><ul><li>Radius Health (NASDAQ:<a href='https://seekingalpha.com/symbol/RDUS' title='Radius Health, Inc.'>RDUS</a>) slips&nbsp;<font color='red'>3%</font>&nbsp;premarket, albeit on only 500 shares, on the heels of its <a href=\"https://seekingalpha.com/pr/17028132-radius-health-announces-committee-medicinal-products-human-use-chmp-will-issue-third-dayminus\" target=\"_blank\">announcement </a>that the European Medicines Agency's Committee for Medicinal Products for Human Use &#40;CHMP&#41; will issue a third Day-180 List of Outstanding Issues related to its marketing application seeking approval for abaloparatide for the treatment of postmenopausal women with osteoporosis.</li><li>CHMP will also refer the application to a scientific advisory group for additional input.</li><li>Abaloparatide, branded as TYMLOS in the U.S., was approved by the FDA in April.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280397-european-regulator-requests-additional-data-related-radius-healths-marketing-application\" target=\"_blank\">European regulator requests additional data related to Radius Health's marketing application for osteoporosis med Eladynos; Ad Com opinion expected year-end</a> (July 21)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3261375-fda-oks-radius-healths-osteoporosis-med-tymlos-shares-11-percent\" target=\"_blank\">FDA OKs Radius Health's osteoporosis med TYMLOS; shares up 11%</a> (April 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318575\" data-linked=\"Radius Health not quite there with European marketing application for osteoporosis med abaloparatide; shares down 3% premarket\" data-tweet=\"$RDUS - Radius Health not quite there with European marketing application for osteoporosis med abaloparatide; shares down 3% premarket https://seekingalpha.com/news/3318575-radius-health-not-quite-european-marketing-application-for-osteoporosis-med-abaloparatide?source=tweet\" data-url=\"https://seekingalpha.com/news/3318575-radius-health-not-quite-european-marketing-application-for-osteoporosis-med-abaloparatide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318571\" data-ts=\"1513345278\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORCL\" target=\"_blank\">ORCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318571-rbc-downgrades-oracle-following-earnings-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RBC downgrades Oracle following earnings report</a></h4><ul><li>        RBC downgrades Oracle (NYSE:<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a>) to Sector Perform from Outperform with a $51 price target.</li><li>               The downgrade follows Oracle&rsquo;s Q2 report, which beat revenue and EPS estimates but included what some considered soft Cloud growth.&nbsp;</li><li>                  Oracle shares are&nbsp;<font color='red'>down 4.9%</font>&nbsp;premarket.&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3318423-oracle-minus-3_8-percent-aftermarket-despite-q2-cloud-revenue-beats-update\" target=\"_blank\">Oracle -3.8% aftermarket despite Q2, Cloud revenue beats (update)</a> (Dec. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318571\" data-linked=\"RBC downgrades Oracle following earnings report\" data-tweet=\"$ORCL - RBC downgrades Oracle following earnings report https://seekingalpha.com/news/3318571-rbc-downgrades-oracle-following-earnings-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3318571-rbc-downgrades-oracle-following-earnings-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318570\" data-ts=\"1513345251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSX\" target=\"_blank\">CSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318570-csx-falls-sharply-on-harrison-medical-leave\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CSX falls sharply on Harrison medical leave</a></h4><ul> <li>CSX (NYSE:<a href='https://seekingalpha.com/symbol/CSX' title='CSX Corporation'>CSX</a>) is down sharply in early trading as investors digest the unexpected <a href=\"https://seekingalpha.com/news/3318483-csx-chief-harrison-take-medical-leave\" target=\"_blank\">medical leave of absence</a> of CEO Hunter Harrison.</li> <li>Citi thinks the development threatens the turnaround plans that Harrison put in place for the railroad company and sees \"meaningful pressure\" on shares in the short term.  Royal Bank of Canada's Walter Spracklin agrees, saying the Harrison absence adds a \"risk premium\" to the stock.</li> <li>On a conference call this morning, acting CEO James Foote said the management team is focused on keeping CSX on the same track.</li> <li>Sources: Bloomberg, <a href=\"https://www.theglobeandmail.com/report-on-business/international-business/us-business/csx-shares-tumble-as-ceo-harrison-announces-medical-leave/article37341829/\" target=\"_blank\">Globe and Mail</a></li> <li>CSX <font color='red'>-12.06%</font> premarket to $50.40.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318570\" data-linked=\"CSX falls sharply on Harrison medical leave\" data-tweet=\"$CSX - CSX falls sharply on Harrison medical leave https://seekingalpha.com/news/3318570-csx-falls-sharply-on-harrison-medical-leave?source=tweet\" data-url=\"https://seekingalpha.com/news/3318570-csx-falls-sharply-on-harrison-medical-leave\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318569\" data-ts=\"1513345150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DISCA\" target=\"_blank\">DISCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318569-john-malone-adds-to-discovery-stake-shares-up-2_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">John Malone adds to Discovery stake; shares up 2.5%</a></h4><ul><li>John Malone discloses<a href=\"https://www.sec.gov/Archives/edgar/data/937797/000120919117065687/xslF345X03/doc4.xml\" target=\"_blank\"> the purchase on Wednesday </a>of 332.5K shares of Discovery Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/DISCA' title='Discovery Inc A'>DISCA</a>), bringing his stake up to about 900K shares.</li><li>The stock's&nbsp;<font color='green'>up 2.5%</font>&nbsp;premarket to $20.54.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318569\" data-linked=\"John Malone adds to Discovery stake; shares up 2.5%\" data-tweet=\"$DISCA - John Malone adds to Discovery stake; shares up 2.5% https://seekingalpha.com/news/3318569-john-malone-adds-to-discovery-stake-shares-up-2_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3318569-john-malone-adds-to-discovery-stake-shares-up-2_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318568\" data-ts=\"1513345124\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABC\" target=\"_blank\">ABC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318568-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>AmerisourceBergen (NYSE:<a href='https://seekingalpha.com/symbol/ABC' title='AmerisourceBergen Corporation'>ABC</a>) upgraded to Buy with a $105 (18% upside) price target by Goldman Sachs.</li><li>Biohaven Pharmaceutical Holding (NYSE:<a href='https://seekingalpha.com/symbol/BHVN' title='Biohaven Pharmaceutical Holding Company Ltd.'>BHVN</a>) initiated with Buy rating by Canaccord Genuity.</li><li>Restoration Robotics (NASDAQ:<a href='https://seekingalpha.com/symbol/HAIR' title='Restoration Robotics'>HAIR</a>) initiated with Buy rating and $7.50 (39% upside) price target by Roth Capital.</li><li>IQVIA Holdings (NYSE:<a href='https://seekingalpha.com/symbol/IQV' title='IQVIA Holdings, Inc.'>IQV</a>) initiated with Neutral rating and $112 (10% upside) price target by MUFG.</li><li>Intra-Cellular Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies Inc.'>ITCI</a>) initiated with Buy rating and $31 (108% upside) price target by Canaccord.</li><li>PRA Health Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/PRAH' title='PRA Health Sciences'>PRAH</a>) initiated with Overweight rating and $102 (15% upside) price target by MUFG. Shares up a fraction premarket.</li><li>Rigel Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a>) initiated with Overweight rating and $6 (68% upside) price target by Cantor Fitzgerald. Shares up&nbsp;<font color='green'>4%</font>&nbsp;premarket.</li><li>Express Scripts (NASDAQ:<a href='https://seekingalpha.com/symbol/ESRX' title='Express Scripts, Inc.'>ESRX</a>) upgraded to Outperform with an $81 (17% upside) price target by Baird. Shares are up a fraction premarket.</li><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) upgraded to Buy with a $20 (16% upside) price target by Goldman Sachs. Shares up&nbsp;<font color='green'>4%</font>&nbsp;premarket on robust volume.</li><li>Cardiovascular Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CSII' title='Cardiovascular Systems, Inc.'>CSII</a>) downgraded to Hold by Needham.</li><li>Amgen (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) removed from Conviction Buy list at Goldman.</li><li>BioMarin Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a>) and Alnylam Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) added to Conviction Buy list at Goldman. AMGN up&nbsp;<font color='green'>2%</font>&nbsp;premarket. ALNY up&nbsp;<font color='green'>5%&nbsp;</font>premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318568\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$ABC $ABC $BHVN - Premarket analyst action - healthcare https://seekingalpha.com/news/3318568-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3318568-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318565\" data-ts=\"1513344737\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIT\" target=\"_blank\">FIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318565-stifel-downgrades-fitbit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel downgrades Fitbit</a></h4><ul><li>        Stifel <a href=\"http://news.morningstar.com/all/market-watch/TDJNMW20171215156/update-fitbit-stock-falls-as-stifel-nicolaus-sees-no-sightlines-to-profitability.aspx\" target=\"_blank\">downgrades</a> Fitbit (NYSE:<a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a>) from Hold to Sell with a $6 price target.</li><li>               The firm says Fitbit has to clear a &ldquo;high hurdle&rdquo; to break even on operating margin.&nbsp;</li><li>               The analyst note, led by analyst Jim Duffy, says Fitbit lacks &ldquo;visibility to monetization of healthcare opportunities&rdquo; and doesn&rsquo;t stand to benefit from corporate tax reforms.&nbsp;</li><li>               Fitbit shares are&nbsp;<font color='red'>down 4%</font>&nbsp;premarket. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3318565\" data-linked=\"Stifel downgrades Fitbit\" data-tweet=\"$FIT - Stifel downgrades Fitbit https://seekingalpha.com/news/3318565-stifel-downgrades-fitbit?source=tweet\" data-url=\"https://seekingalpha.com/news/3318565-stifel-downgrades-fitbit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318562\" data-ts=\"1513344267\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FL\" target=\"_blank\">FL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318562-ringing-upgrade-on-foot-locker-from-canaccord\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ringing upgrade on Foot Locker from Canaccord</a></h4><ul> <li>Foot Locker (NYSE:<a href='https://seekingalpha.com/symbol/FL' title='Foot Locker, Inc.'>FL</a>) breaks higher in early action after the retailer is <a href=\"https://www.cnbc.com/2017/12/15/stocks-making-the-biggest-moves-premarket-orcl-hes-adbe-cost-tmus-fit-more.html\" target=\"_blank\">upgraded</a> by Canaccord Genuity to Buy from Hold.</li> <li>The Canaccord team thinks Foot Locker's strong relationship with Nike is critical as the retail landscape changes.</li> <li>The eye-popping price target on Foot Locker from Canaccord is $64. The PT reps +40% upside for new investors and is well-above the consensus Street PT of $47.</li> <li>Shares of Foot Locker are <font color='green'>up 2.68%</font> premarket to $45.52 on volume of over 4K.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318562\" data-linked=\"Ringing upgrade on Foot Locker from Canaccord\" data-tweet=\"$FL - Ringing upgrade on Foot Locker from Canaccord https://seekingalpha.com/news/3318562-ringing-upgrade-on-foot-locker-from-canaccord?source=tweet\" data-url=\"https://seekingalpha.com/news/3318562-ringing-upgrade-on-foot-locker-from-canaccord\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318561\" data-ts=\"1513344038\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIGL\" target=\"_blank\">RIGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318561-rigel-announces-departure-of-cfo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rigel announces departure of CFO</a></h4><ul><li>Rigel Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RIGL' title='Rigel Pharmaceuticals, Inc.'>RIGL</a>) <a href=\"https://seekingalpha.com/pr/17028129-rigel-announces-departure-chief-financial-officer\" target=\"_blank\">announces</a> the resignation of Ryan Maynard, executive VP and CFO, effective December 31. Nelson Cabatuan, Rigel's VP, finance will serve as the company's interim principal accounting officer.</li>                   <li>The Company has initiated an external search for its next CFO.</li><li>Shares are up&nbsp;<font color='green'>3%</font>&nbsp;premarket on light volume.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3318561\" data-linked=\"Rigel announces departure of CFO\" data-tweet=\"$RIGL - Rigel announces departure of CFO https://seekingalpha.com/news/3318561-rigel-announces-departure-of-cfo?source=tweet\" data-url=\"https://seekingalpha.com/news/3318561-rigel-announces-departure-of-cfo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318560\" data-ts=\"1513343894\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RENN\" target=\"_blank\">RENN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318560-renrenplus-4_4-on-q3-results-subsidiary-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Renren +4.4% on Q3 results, subsidiary update</a></h4><ul><li>        Renren (NYSE:<a href='https://seekingalpha.com/symbol/RENN' title='Renren Inc.'>RENN</a>) shares are&nbsp;<font color='green'>up 4.4%</font>&nbsp;premarket after reporting Q3 results. Q4 guidance has revenue from $95M to $100M, which would represent a 367% to 392% growth on the year.</li><li>        Revenue breakdown: Advertising and Internet Value-Added Services revenue, $12.9M (+34.6% Y/Y); financing income, $6.6M (-20.2%); Used car sales, $42.3M.</li><li>               Subsidiary update: Renren still plans to dispose of a new subsidiary holding its ad agency business and most of its minority stakes in investee companies. The company is waiting for approval from the New York Department of Financial Services, which is required to transfer Renren&rsquo;s shares of Social Finance (a mortgage banker license holder in the state) into the subsidiary.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17028051-renren-announces-unaudited-third-quarter-2017-financial-results-updates-proposed-transaction\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318503-renren-reports-q3-results\" target=\"_blank\">Renren reports Q3 results</a> (Dec. 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318560\" data-linked=\"Renren +4.4% on Q3 results, subsidiary update\" data-tweet=\"$RENN - Renren +4.4% on Q3 results, subsidiary update https://seekingalpha.com/news/3318560-renrenplus-4_4-on-q3-results-subsidiary-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3318560-renrenplus-4_4-on-q3-results-subsidiary-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318559\" data-ts=\"1513343847\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKTR\" target=\"_blank\">NKTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318559-nektar-therapeutics-down-1-premarket-after-bayer-bails-on-agreement-to-develop-inhaled\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nektar Therapeutics down 1% premarket after Bayer bails on agreement to develop inhaled amikacin</a></h4><ul><li>Nektar Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a>) slips&nbsp;<font color='red'>1%</font>&nbsp;premarket on light volume in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/906709/000161577417007343/s108441_8k.htm\" target=\"_blank\">announcement </a>that Bayer Healthcare (<a href='https://seekingalpha.com/symbol/BAYRY' title='Bayer A.G. ADR'>OTCPK:BAYRY</a>) has formally notified the company that it intends to terminate their August 2007 agreement to develop Amikacin Inhale.</li><li>Putting a positive spin on the news, Nektar says it has no payment obligations related to the termination and it will avoid investing $25M - 30M over the next 12 - 18 months to scale up manufacturing per the contract.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318559\" data-linked=\"Nektar Therapeutics down 1% premarket after Bayer bails on agreement to develop inhaled amikacin\" data-tweet=\"$NKTR $NKTR $BAYRY - Nektar Therapeutics down 1% premarket after Bayer bails on agreement to develop inhaled amikacin https://seekingalpha.com/news/3318559-nektar-therapeutics-down-1-premarket-after-bayer-bails-on-agreement-to-develop-inhaled?source=tweet\" data-url=\"https://seekingalpha.com/news/3318559-nektar-therapeutics-down-1-premarket-after-bayer-bails-on-agreement-to-develop-inhaled\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318540\" data-ts=\"1513341985\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318540-fda-lifts-clinical-hold-on-alnylams-fitusiran-shares-up-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA lifts clinical hold on Alnylam&#39;s fitusiran; shares up 6% premarket</a></h4><ul><li>The FDA has <a href=\"https://seekingalpha.com/pr/17028100-fda-lifts-clinical-hold-fitusiran\" target=\"_blank\">removed </a>the clinical hold on studies of Alnylam's (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) hemophilia candidate fitusiran, instituted in September after a hemophilia A patient died from a blood clot.</li><li>Clinical trials may now resume with new clinical risk mitigation measures including protocol-specific guidelines and additional investigator and patient education related to reduced doses of replacement factor or bypassing agent to treat any breakthrough bleeds.</li><li><a href=\"http://www.alnylam.com/web/assets/Hemophilia-Overview-Fitusiran-Update.pdf\" target=\"_blank\">Fitusiran</a>, administered once-monthly via subcutaneous injection, is an investigational RNAi therapeutic targeting antithrombin &#40;AT&#41;, a naturally occurring protein that interferes with certain enzymes involved in blood clotting. Lowering AT promotes the generation of an enzyme called thrombin which plays an essential role in clotting.</li><li>The company is developing fitusiran with Sanofi Genzyme (NASDAQ:<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a>) under a November 2016 agreement.</li><li>ALNY is up&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294061-alnylam-suspends-mid-stage-extension-study-hemophilia-candidate-fitusiran-patient-death\" target=\"_blank\">Alnylam suspends mid-stage extension study of hemophilia candidate fitusiran after patient death; shares down 23%</a> (Sept. 7)</li><li>Previously:&nbsp;<a href=\"https://seekingalpha.com/news/3224205-sanofi-genzyme-commits-develop-commercialize-hemophilia-candidate-alnylam\" target=\"_blank\">Sanofi Genzyme commits to develop and commercialize hemophilia candidate with Alnylam</a>&nbsp;(Nov. 14, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318540\" data-linked=\"FDA lifts clinical hold on Alnylam&#39;s fitusiran; shares up 6% premarket\" data-tweet=\"$ALNY $ALNY $SNY - FDA lifts clinical hold on Alnylam&#39;s fitusiran; shares up 6% premarket https://seekingalpha.com/news/3318540-fda-lifts-clinical-hold-on-alnylams-fitusiran-shares-up-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3318540-fda-lifts-clinical-hold-on-alnylams-fitusiran-shares-up-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318532\" data-ts=\"1513341212\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACRS\" target=\"_blank\">ACRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318532-fda-oks-aclaris-eskata-for-seborrheic-keratoses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Aclaris&#39; Eskata for seborrheic keratoses</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17028114-aclaris-therapeutics-receives-fda-approval-eskata-hydrogen-peroxide-topical-solution-40\" target=\"_blank\">approves </a>Aclaris Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/ACRS' title='Aclaris Therapeutics'>ACRS</a>) ESKATA (hydrogen peroxide) topical solution, 40% for the treatment of raised seborrheic keratoses (non-cancerous skin growths).</li><li>The product is designed for in-office application by a healthcare provider via a pen-like applicator. Market launch will commence in the spring of 2018.</li><li>Management will host a conference call this morning at 8:00 am ET to discuss the approval.</li><li><strong>Update</strong>: Shares are up&nbsp;<font color='green'>10%</font>&nbsp;premarket on light volume.</li><li><strong>Update</strong>: On May 7, the company <a href=\"https://seekingalpha.com/pr/17154221-aclaris-therapeutics-announces-availability-eskata-hydrogen-peroxide-topical-solution-40\" target=\"_blank\">announced </a>the U.S. launch.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318532\" data-linked=\"FDA OKs Aclaris&#39; Eskata for seborrheic keratoses\" data-tweet=\"$ACRS - FDA OKs Aclaris&#39; Eskata for seborrheic keratoses https://seekingalpha.com/news/3318532-fda-oks-aclaris-eskata-for-seborrheic-keratoses?source=tweet\" data-url=\"https://seekingalpha.com/news/3318532-fda-oks-aclaris-eskata-for-seborrheic-keratoses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318534\" data-ts=\"1513341059\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RYAAY\" target=\"_blank\">RYAAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318534-ryanair-agrees-to-pilot-unions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ryanair agrees to pilot unions</a></h4><ul><li>Ryanair (NASDAQ:<a href='https://seekingalpha.com/symbol/RYAAY' title='Ryanair Holdings PLC'>RYAAY</a>) is down sharply after the airline company <a href=\"https://www.nytimes.com/2017/12/15/business/ryanair-pilot-unions.html\" target=\"_blank\">agrees</a> to recognize pilot unions across Europe for the first time.</li><li>The budget carrier was facing a pilot strike right in front of the Christmas holiday.</li><li>Shares of Ryanair are&nbsp;<font color='red'>down 5.77%</font>&nbsp;in London trading on concerns over the additional union-related costs.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318534\" data-linked=\"Ryanair agrees to pilot unions\" data-tweet=\"$RYAAY - Ryanair agrees to pilot unions https://seekingalpha.com/news/3318534-ryanair-agrees-to-pilot-unions?source=tweet\" data-url=\"https://seekingalpha.com/news/3318534-ryanair-agrees-to-pilot-unions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318530\" data-ts=\"1513340434\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSTM\" target=\"_blank\">VSTM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318530-verastem-readies-equity-offering-shares-down-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verastem readies equity offering; shares down 8% premarket</a></h4><ul><li>Verastem (NASDAQ:<a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a>) slips&nbsp;<font color='red'>8%</font>&nbsp;premarket on light volume in response to its planned <a href=\"https://seekingalpha.com/pr/17027943-verastem-announces-public-offering-common-stock\" target=\"_blank\">public offering</a> of $25M of common stock. Price and terms have yet to be announced.</li><li>Yesterday's close was $3.65.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318530\" data-linked=\"Verastem readies equity offering; shares down 8% premarket\" data-tweet=\"$VSTM - Verastem readies equity offering; shares down 8% premarket https://seekingalpha.com/news/3318530-verastem-readies-equity-offering-shares-down-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3318530-verastem-readies-equity-offering-shares-down-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318528\" data-ts=\"1513340240\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TROV\" target=\"_blank\">TROV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318528-trovagene-prices-equity-offering-shares-down-30-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TrovaGene prices equity offering; shares down 30% premarket</a></h4><ul><li>TrovaGene (NASDAQ:<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a>) slumps&nbsp;<font color='red'>30%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/17028066-trovagene-prices-4_5-million-public-offering\" target=\"_blank\">public offering</a> of 15M shares of common stock and warrants to purchase up to 15M shares of common at $0.30 per share and warrant.</li><li>Each five-year warrant is immediately exercisable at $0.30 per common share. Closing date is December 19.</li><li>Net proceeds of ~$4.1M will fund R&amp;D, working capital and general corporate purposes.</li><li>Yesterday's close was $0.43.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318528\" data-linked=\"TrovaGene prices equity offering; shares down 30% premarket\" data-tweet=\"$TROV - TrovaGene prices equity offering; shares down 30% premarket https://seekingalpha.com/news/3318528-trovagene-prices-equity-offering-shares-down-30-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3318528-trovagene-prices-equity-offering-shares-down-30-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318525\" data-ts=\"1513339862\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGLT\" target=\"_blank\">EGLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318525-fda-tentatively-oks-expanded-label-for-egalets-pain-med-arymo-er-shares-up-31-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA tentatively OKs expanded label for Egalet&#39;s pain med Arymo ER; shares up 31% premarket</a></h4><ul><li>Nano cap Egalet (<a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a>) is up&nbsp;<font color='green'>31%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17028076-egalet-receives-fda-tentative-approval-expanded-label-arymo-er-morphine-sulfate-c-ii-extended\" target=\"_blank\">announcement </a>that the FDA has tentatively approved new labeling for opioid pain med ARYMO ER (morphine sulfate) extended-release tablets C-II.</li><li>The new labeling will include data from a Category 2/3 intranasal human abuse potential study and an intranasal abuse-deterrent claim.</li><li>Tentative approval means that the application was complete enough for full approval but patent issues need to be resolved. In this case, the date for patent exclusivity will expire on October 2, 2018.</li><li>ARYMO ER incorporates the company's&nbsp;<a href=\"http://egalet.com/rd/technology-overview/\" target=\"_blank\">Guardian Technology</a>&nbsp;which uses injection molding to create a hard matrix designed to make the pill difficult to crush, grind, chew or dissolve. It also turns to gel when exposed to water.</li></ul><div class=\"tiny-share-widget\" data-id=\"3318525\" data-linked=\"FDA tentatively OKs expanded label for Egalet&#39;s pain med Arymo ER; shares up 31% premarket\" data-tweet=\"$EGLT $ZCOR - FDA tentatively OKs expanded label for Egalet&#39;s pain med Arymo ER; shares up 31% premarket https://seekingalpha.com/news/3318525-fda-tentatively-oks-expanded-label-for-egalets-pain-med-arymo-er-shares-up-31-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3318525-fda-tentatively-oks-expanded-label-for-egalets-pain-med-arymo-er-shares-up-31-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3318520\" data-ts=\"1513339017\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFE\" target=\"_blank\">PFE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3318520-fda-oks-pfizers-xeljanz-for-psoriatic-arthritis-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Pfizer&#39;s Xeljanz for psoriatic arthritis; shares up 1% premarket</a></h4><ul><li>As expected, the FDA <a href=\"https://seekingalpha.com/pr/17027991-pfizer-announces-fda-approval-xeljanz-tofacitinib-xeljanz-xr-treatment-active-psoriatic\" target=\"_blank\">approves </a>Pfizer's (NYSE:<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>) JAK inhibitor XELJANZ (tofacitinib) for the treatment of adult patients with active psoriatic arthritis who have not responded adequately or are intolerant of methotrexate or other disease-modifying antirheumatic drugs (DMARDs).</li><li>An FDA advisory committee voted 10 - 1 in favor of approval in August.</li><li>XELJANZ was first approved in the U.S. for rheumatoid arthritis in November 2012.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3285405-fda-ad-com-backs-pfizers-xeljanz-psoriatic-arthritis-shares-ahead-2-percent\" target=\"_blank\">FDA Ad Com backs Pfizer's Xeljanz for psoriatic arthritis; shares ahead 2%</a> (Aug. 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3318520\" data-linked=\"FDA OKs Pfizer&#39;s Xeljanz for psoriatic arthritis; shares up 1% premarket\" data-tweet=\"$PFE - FDA OKs Pfizer&#39;s Xeljanz for psoriatic arthritis; shares up 1% premarket https://seekingalpha.com/news/3318520-fda-oks-pfizers-xeljanz-for-psoriatic-arthritis-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3318520-fda-oks-pfizers-xeljanz-for-psoriatic-arthritis-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":59,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}